Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study

By S. Wild, T. Pierpoint, P. McKeigue, H. Jacobs. Clinical Endocrinology, 2000

702 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/e26b7a1ddc988c397e50fa40b00da4dba9fcd29e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Reproductive Medicine

Citations in the corpus

Epidemiology, diagnosis, and management of polycystic ovary syndrome (2013, background): “A retrospective cohort study by Wild et al was unable to demonstrate a significant increase in coronary heart disease morbidity and mortality in women with PCOS.(86) However, cerebrovascular disease was more prevalent in women with PCOS after adjustment for BMI (OR 3.”
Androgens and cardiovascular disease. (2003, neutral): “Lower but more sustained exposure to androgen excess in women with polycystic ovary syndrome is also associated with no excess of cardiovascular disease (38) or mortality (39), despite increases in cardiovascular risk factors (40, 41), endometrial (but not breast) cancer (42), and more extensive ath”
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. (2010, background): “in classic PCOS in the United States is 33–47% (12, 33, 43, 66, 67), about two to three times higher than that of age-”
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). (2004, background): “There is now clear evidence that women with PCOS are at increased (3±7 times) risk of developing type 2 diabetes (Dunaif et al., 1987; Dahlgren et al., 1992a; Ehrmann et al., 1999; Legro et al., 1999; Wild et al., 2000).”
Androgens and coronary artery disease. (2003, background): “However, both these studies suffer from methodological drawbacks such as underascertainment of PCOS (79, 80) and the relative young age of the smaller cohort (81).”
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. (2014, positive): “Some of the studies including very high numbers of women point towards an increase in either CV morbidity and even mortality in women with irregular menses (197, 198), or increased incidence of stroke in PCOS women from the UK (199).”